Acute promyelocytic leukemia: Difference between revisions
No edit summary |
No edit summary |
||
| Line 40: | Line 40: | ||
==Treatment== | ==Treatment== | ||
[[Acute promyelocytic leukemia medical therapy|Medical Therapy | [[Acute promyelocytic leukemia medical therapy|Medical Therapy]] | [[Acute promyelocytic leukemia medical therapy#Supportive Therapy|Supportive Therapy]] | ||
==Case Studies== | ==Case Studies== | ||
Revision as of 15:40, 17 September 2012
Template:DiseaseDisorder infobox
|
Acute promyelocytic leukemia Microchapters |
|
Differentiating Acute promyelocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute promyelocytic leukemia On the Web |
|
American Roentgen Ray Society Images of Acute promyelocytic leukemia |
|
Directions to Hospitals Treating Acute promyelocytic leukemia |
|
Risk calculators and risk factors for Acute promyelocytic leukemia |
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Acute progranulocytic leukemia; APL; AML with t(15;17)(q22;q12); PML-RARA and variants; FAB subtype M3; M3 variant
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Acute promyelocytic leukemia from Other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Other Imaging studies | Other Diagnostic Studies
Treatment
Medical Therapy | Supportive Therapy